61
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Low-density lipoprotein cholesterol outcomes post-non-PCSK9i lipid-lowering therapies in atherosclerotic cardiovascular disease and probable heterozygous familial hypercholesterolemia patients

, , , , &
Pages 2425-2435 | Published online: 13 Dec 2018

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Seth J Baum, Rolin L Wade, Pin Xiang, Jorge Arellano, Cesar Cerezo Olmos, Sasikiran Nunna, Chi-Chang Chen, Cathryn M Carter & Nihar R Desai. (2019) Demographic And Clinical Characteristics Of Patients Prescribed Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor Therapy And Patients Whose Current Lipid-Lowering Therapy Was Modified. Therapeutics and Clinical Risk Management 15, pages 1325-1332.
Read now

Articles from other publishers (1)

Daniel Gaudet, Ronen Durst, Norman Lepor, Rebecca Bakker-Arkema, Charles Bisgaier, Liz Masson, Lee Golden, John J. Kastelein, Robert A. Hegele & Evan Stein. (2019) Usefulness of Gemcabene in Homozygous Familial Hypercholesterolemia (from COBALT-1). The American Journal of Cardiology 124:12, pages 1876-1880.
Crossref